Activation of PI3K/AKT and MAPK Pathway through a PDGFRβ-Dependent Feedback Loop Is Involved in Rapamycin Resistance in Hepatocellular Carcinoma
Open Access
- 9 March 2012
- journal article
- biology
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (3), e33379
- https://doi.org/10.1371/journal.pone.0033379
Abstract
Rapamycin is an attractive approach for the treatment and prevention of HCC recurrence after liver transplantation. However, the objective response rates of rapamycin achieved with single-agent therapy were modest, supporting that rapamycin resistance is a frequently observed characteristic of many cancers. Some studies have been devoted to understanding the mechanisms of rapamycin resistance, however, the mechanisms are cell-type-dependent and studies on rapamycin resistance in HCC are extremely limited. The anti-tumor sensitivity of rapamycin was modest in vitro and in vivo. In both human and rat HCC cells, rapamycin up-regulated the expression and phosphorylation of PDGFRβ in a time and dose-dependent manner as assessed by RT-PCR and western blot analysis. Using siRNA mediated knockdown of PDGFRβ, we confirmed that subsequent activation of AKT and ERK was PDGFRβ-dependent and compromised the anti-tumor activity of rapamycin. Then, blockade of this PDGFRβ-dependent feedback loop by sorafenib enhanced the anti-tumor sensitivity of rapamycin in vitro and in an immunocompetent orthotopic rat model of HCC. Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop compromises the anti-tumor activity of rapamycin in HCC, and blockade of this feedback loop by sorafenib is an attractive approach to improve the anti-tumor effect of rapamycin, particularly in preventing or treating HCC recurrence after liver transplantation.Keywords
This publication has 31 references indexed in Scilit:
- mTOR-Dependent Regulation of PHLPP Expression Controls the Rapamycin Sensitivity in Cancer CellsOnline Journal of Public Health Informatics, 2011
- Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3World Journal of Gastroenterology, 2011
- Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case reportWorld Journal of Gastroenterology, 2010
- Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell LinesPLOS ONE, 2009
- Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinomaJournal of Cellular and Molecular Medicine, 2009
- Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitorsCell Cycle, 2008
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJCI Insight, 2008
- PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTORJCI Insight, 2007
- Predicted mechanisms of resistance to mTOR inhibitorsBritish Journal of Cancer, 2006
- p73 Independent of c-Myc Represses Transcription of Platelet-derived Growth Factor β-Receptor through Interaction with NF-YOnline Journal of Public Health Informatics, 2002